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Introduction
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The human papillomavirus (HPV) is associated with several forms of cancer including
anal, oral, penile and cervical (Gilbert, Brewer, Reiter, Ng, & Smith, 2010). The initiation of
Papinicoau (Pap) screening over 30 years ago to detect cervical dysplasia (often caused by HPV)
resulted in early detection and treatment and a dramatic decline in deaths from cervical cancer
(Palefsky, 2009).
Nationally standardized cervical cancer screening exists for HPV related cervical cancer,
however, universal screening protocols for HPV associated anal cancer is non-existent (Palefsky,
2009). In 1973, the rate of cervical cancer was 14.2 per 100,000, but with the advent of cervical
Pap screening it has decreased to approximately 8 per 100,000 (Nanda, et al, 2000, Palefsky,
1999).
With the success of standardized cervical screening protocols, it is fair to suggest that
similar screening protocols may be efficacious in the early detection of anal cancer. A screening
protocol for early detection and treatment of anal cancer, aimed at high-risk groups, such as men
who have sex with men (MSM), could theoretically demonstrate reductions similar to cervical
cancer, in deaths and morbidity from anal cancer.
HPV and Anal Cancer
Epidemiology
Statistically, anal cancer is rare; however, incidence varies by risk group. In 2009, the
American Cancer Society reported that there were 5290 new cases of anal cancer (3190 females
and 2100 males). Seven hundred and ten deaths (450 females and 260 men) were caused by anal
cancer (The American Cancer Society, 2009). Johnson, et al. (2004) found that among the
general population diagnosis of anal cancer is 1.7 per 100,000 people, with women having a
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slightly higher incidence. Between 1998 through 2003, black men and women were diagnosed
with anal cancer at a rate of 1.2 and 1.3, respectively (Centers for Disease Control [CDC], 2011).
Among HIV positive and negative men who have sex with men, statistics are drastically
higher. The incidence of anal cancer among men who have sex with men is estimated at 35 per
100,000, statistics that are similar to the incidence of cervical cancer prior to the implementation
of routine screening programs (Friedlander, et al., 2003; Arain, et al, 2005). Prior to the HIV
epidemic, the incidence of anal cancer was 35 cases per 100,000; after HIV and AIDS became
prevalent the incidence of anal cancer soared to 70 cases per 100,000 in men who have sex with
men (Palefsky, 1999; Oon & Winter, 2010).
Individuals with compromised immune systems, as in HIV and AIDs, have a higher
incidence of developing anal cancer. The likelihood of developing anal cancer in men with a comorbid condition of HIV, increases thirty-five fold (Chaturvedi, 2010). The mean age of
diagnosis of anal carcinoma in HIV positive males is 40.9 years, compared with the general
population at around age 60 (Frisch, Biggar, & Goedert, 2000).
Pathophysiology, Histology, & Virology
The natural progression of anal cancer isn’t clearly understood; however a correlation has
been established between the human papillomavirus (HPV) and dysplastic effects, the precursor
to anal cancer (Chaturvedi, 2010). It is believed that the etiology of anal squamous cell
carcinoma is equivalent to cancer of the cervix. More than eighty genomes of HPV exist, and of
those, nine types of genomes have been identified with anal dysplasia and cancer. The high risk
genotypes HPV 16 and HPV 18 are most prevalently linked to various types of cancer, including
cervical, oral, and anal (zur Hausen, 1999; Abbas, Yang, & Fakih, 2010a, Palmer, et al, 1988).
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Eighty-eight to 91% of anal cancers are caused by HPV 16 and 18 (Oon & Winter, 2010). Of the
2100 males diagnosed with anal cancer in 2009, 80% of those cases were associated with HPV
oncogenes 16 and 18 (Kim, 2010). Similar to cervical cancer, anal cancer typically develops in
the transformation zone, where the change from columnar epithelium to squamous epithelium
occurs (Palefsky, 1999). The progression of HPV related anal dysplasia and cancer is
accelerated when immunosuppression coexists with the human papillomavirus (Panther, Schlect,
&Dezube, 2005).
Risk Factors and Transmission
Multiple risk factors are associated with anal cancer, including HPV infection, receptive
anal intercourse, number of lifetime partners, cigarette smoking, and history of genital warts
(Abbas, et al, 2010a). Daling, et al. (1987) found that history of anal receptive intercourse,
genital warts, gonorrhea, and cigarette smoking were associated with an increased incidence of
anal cancer. Individuals with HIV who have lower CD4 counts, syphilis, anal warts, or hepatitis
also pose a greater risk for developing anal cancer (Palefsky, 1999; Frisch, et al, 1997).
Giuliano, et al, (2011) reports that the immune response to the human papillomavirus in men is
lower than in women causing higher rates of HPV infection in the male population.
Clinical Presentation
HPV related anal carcinoma presents with a wide array of symptoms. The range of
symptoms in anal carcinoma include being asymptomatic to weight loss, rectal bleeding,
abdominal pain, change in bowel habits, and pain with anal receptive sex (Dyson & Draganov,
2009; Panther, et al, 2005). Nearly fifty percent of patients present with rectal bleeding, while
thirty percent present with feelings of a mass or pain, and twenty percent are asymptomatic
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(Abbas, et al, 2010a; Lindsey, et al, 2009). Fifty percent of all anal cancer cases extend into the
rectum or perineal skin, while in 10% of females, anal cancer proliferates into the anovaginal
septum (Abbas, et al, 2010a)
Literature Review
Several studies have examined the utility of using anal Pap screening as first line
detection of anal dysplasia. Examining the reliability of anal Pap screening is the first step in
determining its utility in screening anal dysplasia.
Diagnostic Tool
Table 1 provides a comparison of seven randomized controlled trial, examining the
sensitivity and specificity of anal Papanicolaou screening. Examination of the sensitivity and
specificity of any tests provides the predictive value of correct positives and correct negative
results that lends to the utility of the test. Anal cytology provides screening with a high
sensitivity ranging from 81-98%, assuring a high number of correct positive results.
One may argue that the low rate of specificity or false negatives of anal pap testing is too
low, averaging fifty percent of the seven randomized control trials. However, literature reveals
that anal Pap testing has a similar variable sensitivity and specificity to that of cervical Pap
testing. Nanda, et al (2000), found that in a review of twelve studies, the conventional Pap test
for cervical screening had a sensitivity range from 30%-87% and a specificity from 86%-100%.
Even though cervical dysplasia screening has a variable sensitivity and specificity, its use as a
screening tool has significantly decreased mortality as a result of early detection and screening.
Theoretically, anal dysplasia screening could demonstrate the same reductions in morbidity and
mortality from anal cancer.
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Table 1: Summary of Studies Using Pap test as a Diagnostic Screening Tool for Anal Dysplasia
Author/Title/Year
Arain, et al. The Anal Pap
Smear: Cytomorphology
of squamous
intraepithelial lesions,
2005
Cranston, et al. The
prevalence and predictive
value of abnormal anal
cytology to diagnose anal
dysplasia in a population
of HIV-positive men who
have sex with men, 2007
De Ruiter, et al. A
comparison between
cytology and histology to
detect anal intraepithelial
neoplasia, 1994
Fox, et al. The value of
anal cytology and human
papillomavirus typing in
the detection of anal
intraepithelial neoplasia: a
review of cases from an
anoscopy clinic, 2005
Friedlander, et al.
Anorectal cytology as a
screening tool for anal
squamous lesions, 2003
Palefsky, et al. Anal
cytology as a screening
tool for anal squamous
intraepithelial lesions,
1997

Panther, et al. High
resolution anoscopy
findings for men who have
sex with men: Inacuracy
of anal cytology as a
predictor of histologic
high-grade anal
intraepithelial neoplasia
and the impact of HIV
serostatus, 2004

N/Type of Study
198 Males
Retrospective Design

Findings
High sensitivity (98%) for
detection of ASIL, low
specificity (50%) for
predicting severity

244 MSM and HIV +
Cross Sectional Design

215 MSM
Cross Sectional Design

Findings reported that anal
cytology has positive
predictive value with up to
95.7% accuracy for any
cytological abnormality
and to predict high-grade
dysplagia at 55.9%
accuracy
High sensitivity 88% with
low specificity 16%

99 Males
Cross Sectional Design

Sensitivity 83%
Specificity 38%

51
Cross Sectional Design

Sensitivity 92% and
specificity 50%

658 MSM
Cross Sectional Design

A total of 2958 anal
cytology samples were
collected from 648
subjects. Initial cytology
sensitivity was 69% in
HIV + and 47% in HIV -.
Subsequent anal cytology
samples had a sensitivity
of 81% and 50%
respectively.
Sensitivity 47%
Specificity 90%

153
Cross Sectional Design
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Continued Debate
There has been debate over the utility of anal cytology Pap screenings; as a result of early
studies that suggested its predictive value was not a useful determinant of abnormal anal
cytology. However, more recent studies indicate it may be a worthwhile screening tool. This
could be due to the switch from conventional slides to Thin Prep (Sherman, 1995). In an
examination of 117 conventional Pap smears and 191 Thin-Preps, satisfactory specimens were
found to be 41% and 82.7% respectively (Sherman, 1995). Friedlander, et al. (2003), found that
when compared with conventional Pap smears, Thin-Preps detected eight times more squamous
intraepithelial lesions. While fecal matter, poor preservation, and air drying artifact tends to
obscure conventional smears, Thin-Preps reduce these factors allowing for more satisfactory
specimens for pathological evaluation (Friedlander, Stier, & Lin, 2003, Sherman, et al, 1995).
A Consideration for Self-Collected Anal Cytology Samples
Fear of testing may lead some MSM to avoid screening in the clinic setting. However,
self-collected anal cytology samples provide a potential alternative to clinic testing. Table 2
provides a comparison of three randomized control trials examining the reliability of selfcollected anal cytology samples compared to clinic collected anal cytology samples. Adequacy
of specimens for pathologic review ranged from 80-91% of self-collected and 68-99% in
clinician-collected anal cytology samples. Sensitivity of the samples was provided in two out of
the three randomized control trials and ranged from 60-68% for self-collected and 68-70% in
clinician-collected anal cytology samples. Empirical evidence supports that self-collected anal
cytology samples may provide an alternative option for individuals who may not otherwise seek
screening measures.
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Table 2: Summary of RCTs Comparing Self- and Clinician-Collected Anal Cytology Samples
Author/Title/Year

N

Chin-Hong, et al.
Comparison of patientand clinician-collected
anal cytology samples to
screen for human
papillomavirus-associated
anal intraepithelial
neoplasia in men who
have sex with men. 2008.

125 MSM

Cranston, et al. Selfcollected versus cliniciancollected anal cytology
specimens to diagnose
anal intraepithelial
neoplasia in HIV-positive
men. 2004.

Lampinen, et al.
Randomized clinical
evaluation of selfscreening for anal cancer
precursors in men who
have sex with men. 2006.

Cross Sectional Design

102 MSM
Cross Sectional Design

222 MSM
Cross Sectional Design

Findings
Adequacy of specimens
was 91% for cliniciancollected and 80% for
self-collected specimens.
Sensitivity of cliniciancollected specimens was
68% and self-collected
samples was 60%.
Adequacy of specimens
for pathological review
was 99% in cliniciancollected and 91% in selfcollected samples.
Sensitivity of cliniciancollected samples was
70% and self-collected
was 68%.
Adequacy of specimens
for pathological review
was 92% cliniciancollected and 83% selfcollected. Information on
sensitivity not provided.

It must be clearly understood that the utility of anal Pap screening would not be used to
stage dysplasia, but to determine whether dysplasia is present or absent, similar to that of a
cervical pap smear. If dysplasia is determined, the necessity of high resolution anoscopy and
biopsy would be required to stage the grade of dysplasia.
Recommended Screening
Currently no national guidelines exist and routine screening is not recommended for the
general population, however, recommendations for high risk populations do exist. Initial
screening is recommended for high risk individuals, including HIV-positive and HIV-negative
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men who have sex with men, women who partake in anal receptive intercourse and individuals
who are immunocompromised; the resultant anal cytology is the determinant for future follow
up.
A normal result requires a repeat screening every two years for HIV-negative MSM and
annually for HIV-positive MSM (Panther, et al, 2005). If the anal cytology is read as anything
other than normal, the patient is referred for high resolution anoscopy (HRA), if no lesion if
found then a repeat anal pap is performed in six months (Panther, et al, 2005). If an anal
intraepithelial neoplasia (AIN) grade 1 is found after the biopsy, a repeat pap and HRA after six
months is recommended; if AIN grade 2 or AIN grade 3 is found, the recommendation is to
ablate the dysplastic cells and have a repeat pap and HRA in four to six months (Panther, et al,
2005). After anal cytology has been stable for two exams, screening can return to every twelve
months (Panther, et al, 2005).
Performing Anal Pap Screening
Performing anal Pap screening takes little to no preparation on the patient’s part, no
bowel preparation is necessary, with the exception that the patient may need to evacuate their
bowel prior to the procedure (Porche, 2006). The patient is placed in the left lateral position, and
a Dacron swab that is lubricated with tap water is inserted 1.5 to 2 inches into the rectum. It is
recommended that the swab be rotated 10-12 times while placing lateral pressure against the anal
canal with the swab (Porche, 2006). The swab is then placed in a liquid medium, such as
ThinPrep, and labeled with the patient’s name, and other identifying information (Siekas &
Aboulafia, 2009).
Staging and Prognosis
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Five year survival rates for anal cancer are 80.1% for localized or cancer confined to a
primary site, 59.8% for regional spread to lymph nodes, and 30.5% for anal cancer with
metastatic spread (National Cancer Institute, 2010). Prognosis and survival rates of anal cancer
patients’ worsens with the co-morbitidity of HIV, one year mortality rates are 40% and five year
mortality rates are 80% (Place, Gregorcyk, Huber, & Simmang, 2001).
Cost Effectiveness
Two Markov models were developed to assess the cost-effectiveness of screening for
anal dysplasia and anal cancer among HIV-positive and HIV-negative men who have sex with
men. The studies conducted found that screening HIV-positive MSM either annually or every
two years and HIV-negative men every two to three years, will prolong quality adjusted life
years while remaining cost effective (Goldie, et al, 1999; Goldie, et al, 2000). Both studies
found that the most influential factor was the progression of the lesions, regardless screening
annually for HIV-positive MSM and every two to three years for HIV-negative MSM provided a
accurate screening modality while decreasing the economic burden (Goldie, et al, 1999; Goldie,
Kuntz, Weinstein, Friedberg, & Palefsky, 2000).
Treatment
A broad spectrum of treatments exists and treatment type is determined by the degree of
cellular dysplasia. High-grade anal intraepithelial lesions (the precursor to anal cancer) can be
treated with trichloroacetic acid (either physician or patient applied), photodynamic surgery,
electrocautery, or surgery (Abbas, et al., 2010b). Post surgical complications, include, but are
not limited to bleeding, perianal bleeding, and anal sphincter dysfunction (Chang, Berry, Jay,
Palefsky, & Welton, 2002). Recurrence rates twelve months post surgical was 79% for HIV-
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positive patients and zero recurrence for HIV-negative (Chang, et al, 2002). Anal cancer
treatment typically involves a combination of chemotherapy and radiation (Goldstone, 2005).
Typical treatment for anal cancer begins with a week of chemotherapy, followed by five weeks
of radiation, followed up with another week of chemotherapy (Abbas, 2010b, Goldstone, 2005).
Billing
Careful coding is required to receive reimbursement for anal cytology screening. Two
different billing codes exist for anal cytology, one for using liquid-based cytology, such as
ThinPrep, and the other for conventional slides (Darragh & Winkler, 2004). Coding anal
cytology as a gynecological specimen will lead to reimbursement failure (Darragh & Winkler,
2004).
Barriers to Receiving Screening
Reed, Reiter, Smith, Palefsky, and Brewer (2010), found the biggest barriers to receiving
anal Pap screening among MSM were modifiable beliefs and lack of education. The most
reported reasons for reluctance to testing was cost, lack of knowledge about the test, and
embarrassment about getting the test (Reed, et al, 2010). Understanding that modifiable beliefs
and fears, whether real or perceived, place the provider in a unique position to educate and
inform clients about a necessary screening tool that could potentially save lives.
Education and Counseling
Several targeted interventions can be utilized in the prevention and screening of anal
dysplasia. First, community based and individual education needs to focus on risk factors,
transmission, screening, and vaccination. Community based education campaigns to educate the
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public that anal dysplasia and cancer is a sexually transmitted infection, resultant from having
unprotected anal receptive intercourse with an HPV positive partner. Therefore, routine and
correct condom use is recommended to prevent the spread of HPV.
Second, if a patient is identified as high risk for HPV related anal cancer, education on
the necessity, process, and frequency of screening is warranted. Twenty-three percent of MSM
have ever heard of an anal Pap and 14% had ever received an anal Pap (Reed, et al, 2010). With
these staggering statistics, it is important to stress the necessity of screening. Fear of the
procedure or anal cancer diagnosis can deter patients from asking about or being screened. To
ameliorate potential or real anxiety and fear, careful explanation and sensitivity to individual
concerns is required. Caring for the emotional and psychological aspect of the patient is crucial.
Vaccination
In October 2009, the FDA approved licensure for the use of Gardisil in males ages nine
to twenty-six for the prophylactic role of HPV induced genital condyloma (genital warts),
potential risk factors for the development of anal cancer (CDC, 2010). Yancey, et al (2010) data
synthesis provides further supporting evidence that the quadrivalent vaccine Gardisil not only
creates immunity from genital condyloma, it has the potential to decrease the incidence of HPV
related anal dysplasia and cancer (Yancey, Pitlick, & Forinash, 2010). One obstacle to getting
boys and young men vaccinated is a knowledge gap among this population. According to
Gilbert, et al (2010), in a survey of 247 gay men only 21% thought that the HPV vaccine worked
in men and 18% thought that the vaccination could be administered to males.
In 2011, results from a randomized, placebo-controlled, double-blind study was
published regarding the use of the guadrivalent humanpapilloma vaccine to protect against HPV
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16 and 18, the precursors to anal cancer (Giuliano, et al, 2011). Giuliano, et al, (2011) found that
receiving the three shot HPV regime significantly decreased the incidence of persistent infection
caused by HPV 16, and 18 by 78.7% to 96.0%. Although this study provides concrete evidence
that the quadrivalent HPV vaccine decreases the incidence of persistent HPV infection, further
research needs to be conducted to determine its effects on decreasing the incidence of anal
cancer, as well as oral, vaginal, and vulvar cancers.
Implications for Practice
Empirical data suggests that using anal cytology as a resource for surveillance programs
is reliable and achievable; anal Papanicolaou screening should be considered a first line defense
in early diagnoses. Identification of anal dysplasia prior to it turning into invasive anal cancer is
the goal of any successful screening program. Primary care providers have a responsibility to
serve at risk individuals and this begins with identifying individuals at a higher propensity for
acquiring a disease or developing an illness. Providers’ attitude and willingness to discuss
sexual practices, prevention, screening options, and vaccinations is pivotal to the success of
eliminating HPV related anal cancer in men who have sex with men.
Collecting complete health histories and risk taking behavior analysis is essential in
determining high risk individuals. It is important as clinicians to remember to collect complete
health history and a risk taking behavior analysis to determine at risk individuals. It is not only
important to screen at risk groups, but to also identify other high risk individuals, such as
heterosexual men and women who partake in anal receptive intercourse, are immune suppressed,
and who partake in high-risk sexual behavior. Providers need to not shy away from asking
individuals if they are not only sexually active, but if they participate in anal receptive
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intercourse either currently or in the past. Creating speaking points prior to a patient interview
will assist in developing a comfort level when it comes to asking sometimes uncomfortable
questions.
A critical question is how do we target prevention efforts towards high risk groups when
no national guidelines exist? Of utmost importance, is screening and treating anal dysplasia
prior to it turning into anal cancer through improved prevention and surveillance campaigns.
Clinicians need to be educated on the importance of an anal dysplasia screening program and
trained on how to effectively collect samples. Individuals providing anal cytology screening
need to inform and educate clients about this option, become proficient at performing anal
cytology, and explaining the procedure to clients. Clinicians also need to be aware of follow up
for someone presenting with abnormal anal cytology.
Fear of discrimination can prevent patients from divulging the fact that they have
partaken in high risk behavior/sexual encounters. Due to fear of discrimination, it is important to
provide a welcoming, prejudice-free, safe environment.
Conclusion
HPV related anal dysplasia and cancer is a public health concern, just like other sexually
transmitted infections. Certain individuals and groups have a higher prevalence, including men
who have sex with men, immune compromised individuals, and women with a history of cervical
and/or vulvular dysplasia and cancer. If this cancer is not caught early, it has disastrous effects.
Due to the high rates in of anal dysplasia and cancer in MSM, it is logical to implement a
screening program, similar to the cervical pap screening program. It is fair to estimate that the
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implementation of a universal surveillance program could provide the same epidemiological
results for anal cancer in men who have sex with men.
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Recommended Internet Sites
The internet sites listed below can serve as resources for information regarding anal
dysplasia and cancer, and disease statistics. The gay and lesbian medical association website
provides a database of medical providers and practitioners that support and provide a safe health
care environment for gay, lesbian, and transsexual individuals.
The American Cancer Society http://cancer.org
The National Cancer Institute http://www.cancer.gov
The Center for Disease Control http://www.cdc.gov
American Social Health Association http://www.ashastd.org
World Health Organization http://www.who.int
Gay and Lesbian Medical Association http://www.glma.org
The Rainbow Health Initiative www.rainbowhealth.org
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